Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries
Authors:
Open Access
- 25 January 2011
- journal article
- review article
- Published by Springer Nature in Molecular Medicine
- Vol. 17 (5-6) , 448-456
Abstract
Histone deacetylase (HDAC) inhibitors are emerging as a novel class of potentially therapeutic agents for treating acute injuries of the central nervous system (CNS). In this review, we summarize data regarding the effects of HDAC inhibitor administration in models of acute CNS injury and discuss issues warranting clinical trials. We have previously shown that the pan-HDAC inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h after injury. Using a well-characterized, clinically relevant mouse model of closed head injury, we demonstrated that a single dose of ITF2357 administered 24 h after injury improves neurobehavioral recovery and reduces tissue damage. ITF2357-induced functional improvement was found to be sustained up to 14 d after trauma and was associated with augmented histone acetylation. Single postinjury administration of ITF2357 also attenuated injury-induced inflammatory responses, as indicated by reduced glial accumulation and activation as well as enhanced caspase-3 expression within microglia/macrophages after treatment. Because no specific therapeutic intervention is currently available for treating brain trauma patients, the ability to affect functional outcome by postinjury administration of HDAC inhibitors within a clinically feasible timeframe may be of great importance. Furthermore, a growing body of evidence indicates that HDAC inhibitors are beneficial for treating various forms of acute CNS injury including ischemic and hemorrhagic stroke. Because HDAC inhibitors are currently approved for other use, they represent a promising new avenue of treatment, and their use in the setting of CNS injury warrants clinical evaluation.Keywords
This publication has 92 references indexed in Scilit:
- Promoting axonal rewiring to improve outcome after strokeNeurobiology of Disease, 2010
- Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's DiseaseNeuropsychopharmacology, 2009
- HDAC6 is a target for protection and regeneration following injury in the nervous systemProceedings of the National Academy of Sciences, 2009
- The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic miceProceedings of the National Academy of Sciences, 2008
- HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in ratsBrain Research, 2008
- Isoform-selective histone deacetylase inhibitorsChemical Society Reviews, 2008
- Reoxygenation stress on blood–brain barrier paracellular permeability and edema in the ratMicrovascular Research, 2008
- Sirtuins in mammals: insights into their biological functionBiochemical Journal, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006